Simulations Plus has a compelling story to tell this week: a brand-new collaboration with Nvidia to scale GPU-accelerated, AI-assisted drug modeling workflows — announced on May 6 — landed as the stock was already up 31% in a month. The tension worth watching is straightforward. A credible catalyst is driving the price; insiders are moving the other direction.
The insider angle is the most immediate signal to parse. Founder and director Walter Woltosz — who holds roughly 16% of the company — sold 15,000 shares on May 4 at $15.13, raising $226,950. The company's chief executive, John DiBella, sold a further 1,000 shares the same day at $14.98. DiBella had already sold 1,000 shares on April 15 at $13.37, before the stock's latest leg higher. Woltosz is a systematic seller — he trimmed in October 2025, July 2025, and June 2025 as well — so this is not an isolated alarm. But the timing, one trading day before the Nvidia announcement pushed the stock higher again, is notable context. Net insider disposals over the past 90 days total approximately 17,000 shares worth $255,000 — entirely one-directional selling, with no offsetting purchases on record.
Options positioning has turned sharply more defensive in the past week. The put/call ratio jumped to 1.23, more than 2.2 standard deviations above its 20-day average of 0.48 — the most cautious options setup the stock has shown in recent months. That's a significant rotation: as recently as mid-April, the PCR was running below 0.10, meaning calls heavily dominated. The reversal to a ratio of over 1.2 is large and fast. Borrow availability remains comfortable — availability is sitting well above the zone that would indicate a crowded short — with cost to borrow at 1.25%, up 29% on the week and 58% over the past month. It's rising, but still inexpensive in absolute terms. Short interest at roughly 7% of free float (using the broader float calculation) has climbed about 7% over the past month, adding consistent pressure without spiking dramatically.
The Street has not yet updated its view to reflect the Nvidia partnership or the monthly price move. The most recent analyst action was TD Cowen's April 10 target cut to $16 — essentially the current price — while maintaining a Hold. That action was itself a response to the weak Q4 earnings print, which showed a 6% year-over-year revenue decline despite full-year growth of 13%. The mean analyst target sits near $23.70, implying meaningful theoretical upside from $15.71, but that figure is anchored to pre-April price levels and includes stale inputs. Bear-case concerns centre on stagnating organic growth and the pattern of revenue deceleration in the second half of fiscal 2025. Bulls point to the 22% software revenue growth and expanding proposal activity in biotech. The EV/EBITDA multiple has expanded to 12.2x over the past 30 days, tracking the price recovery; the P/E ratio has risen similarly, now at 17.8x. Neither reads as obviously stretched for a software-adjacent health care name, but the expansion happened fast.
The next earnings print is scheduled for July 1. The last event, in early April, produced a muted 0.3% one-day move but an 8.6% five-day gain — suggesting the market digests results gradually rather than reacting sharply on the day. The Nvidia collaboration adds a new variable: investors now have a genuine AI angle to evaluate alongside the core pharma-simulation franchise. Whether the partnership translates into revenue in the near term, or whether it is primarily a positioning and brand-building exercise, is the question the July print will start to answer.
What to watch: how sell-side coverage responds to the Nvidia announcement — any target upgrades in the next two weeks would represent a meaningful shift from the current Hold-heavy consensus — and whether the founder's selling pace accelerates now that the stock has recovered toward prior levels.
See the live data behind this article on ORTEX.
Open SLP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
